JP7352901B2 - 腫瘍成長を阻害するための材料および方法 - Google Patents

腫瘍成長を阻害するための材料および方法 Download PDF

Info

Publication number
JP7352901B2
JP7352901B2 JP2020519131A JP2020519131A JP7352901B2 JP 7352901 B2 JP7352901 B2 JP 7352901B2 JP 2020519131 A JP2020519131 A JP 2020519131A JP 2020519131 A JP2020519131 A JP 2020519131A JP 7352901 B2 JP7352901 B2 JP 7352901B2
Authority
JP
Japan
Prior art keywords
cancer
composition
amino acids
cancer cells
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536096A (ja
JP2020536096A5 (enExample
Inventor
ビドヤサガー，サダシバン
グプタ，レシュ
ガット，ステフェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amilyfe LLC
Original Assignee
Entrinsic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entrinsic LLC filed Critical Entrinsic LLC
Publication of JP2020536096A publication Critical patent/JP2020536096A/ja
Publication of JP2020536096A5 publication Critical patent/JP2020536096A5/ja
Priority to JP2023144987A priority Critical patent/JP2023171755A/ja
Application granted granted Critical
Publication of JP7352901B2 publication Critical patent/JP7352901B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020519131A 2017-10-02 2018-10-02 腫瘍成長を阻害するための材料および方法 Active JP7352901B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023144987A JP2023171755A (ja) 2017-10-02 2023-09-07 腫瘍成長を阻害するための材料および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023144987A Division JP2023171755A (ja) 2017-10-02 2023-09-07 腫瘍成長を阻害するための材料および方法

Publications (3)

Publication Number Publication Date
JP2020536096A JP2020536096A (ja) 2020-12-10
JP2020536096A5 JP2020536096A5 (enExample) 2021-11-11
JP7352901B2 true JP7352901B2 (ja) 2023-09-29

Family

ID=64049688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519131A Active JP7352901B2 (ja) 2017-10-02 2018-10-02 腫瘍成長を阻害するための材料および方法
JP2023144987A Pending JP2023171755A (ja) 2017-10-02 2023-09-07 腫瘍成長を阻害するための材料および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023144987A Pending JP2023171755A (ja) 2017-10-02 2023-09-07 腫瘍成長を阻害するための材料および方法

Country Status (7)

Country Link
US (1) US12109191B2 (enExample)
EP (1) EP3691628A1 (enExample)
JP (2) JP7352901B2 (enExample)
KR (1) KR102709096B1 (enExample)
CN (2) CN111417391B (enExample)
CA (1) CA3078335A1 (enExample)
WO (1) WO2019070750A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
US12310936B2 (en) * 2018-05-22 2025-05-27 Seleq Oy Pharmaceutical compositions for the treatment of cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
CN115697301A (zh) * 2020-05-29 2023-02-03 佛罗里达大学研究基金会公司 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006834A1 (en) 1991-10-07 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Enteral preparation for cancer therapy
JP2005097280A (ja) 2003-08-27 2005-04-14 Aaku Giken:Kk 抗腫瘍活性剤
WO2017053328A1 (en) 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
WO1993006934A1 (en) 1991-09-30 1993-04-15 Devtech Labs, Inc. Electrostatic separation of plastic materials
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
JP3429327B2 (ja) 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
EP3701945A1 (en) * 2004-08-09 2020-09-02 Enrique Melendez Hevia Glycine composition for use in the prevention and/or treatment of cancer in a humand in need of promoting the synthesis of collagen
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
EP3016531A4 (en) * 2013-07-01 2017-05-10 The Trustees Of Princeton University Dietary supplements and composition for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006834A1 (en) 1991-10-07 1993-04-15 Otsuka Pharmaceutical Factory, Inc. Enteral preparation for cancer therapy
JP2005097280A (ja) 2003-08-27 2005-04-14 Aaku Giken:Kk 抗腫瘍活性剤
WO2017053328A1 (en) 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Also Published As

Publication number Publication date
US20200323820A1 (en) 2020-10-15
US12109191B2 (en) 2024-10-08
CN111417391B (zh) 2024-06-18
CN118078810A (zh) 2024-05-28
WO2019070750A1 (en) 2019-04-11
JP2023171755A (ja) 2023-12-05
CA3078335A1 (en) 2019-04-11
EP3691628A1 (en) 2020-08-12
KR20200060492A (ko) 2020-05-29
JP2020536096A (ja) 2020-12-10
CN111417391A (zh) 2020-07-14
KR102709096B1 (ko) 2024-09-23

Similar Documents

Publication Publication Date Title
JP2023171755A (ja) 腫瘍成長を阻害するための材料および方法
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
JP5377968B2 (ja) 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
CN110062621A (zh) 氨基酸组合物及其用途
BRPI0721626A2 (pt) combinaÇço farmacÊutica sinergÍstica para o tratamento de cÂncer
EA028452B1 (ru) Лечение рака молочной железы
TW201707704A (zh) 激酶調節及其適應症
WO2010033771A2 (en) Modulators of hsp70/dnak function and methods of use thereof
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
JP2023018029A (ja) 癌の処置のための医薬組成物および方法
AU2018242612A1 (en) Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
US20230277522A9 (en) Methods for treating vascular malformations
CN104918630A (zh) 抗药性癌细胞的抑制
AU2020279003B2 (en) Oxathiazin compounds for inhibiting GAPDH
JP2020508290A (ja) ゴシポールおよびフェンホルミンを有効成分として含む膵臓癌予防および治療用薬学的組成物
TWI891650B (zh) 治療血管畸形之方法
US20220289686A1 (en) Compositions of nrf2 inhibiting agents and methods of use thereof
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
US20240122937A1 (en) Treating cancer in patient with pten inactivating mutation
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
JP2002114673A (ja) 抗悪性腫瘍剤
TW202005664A (zh) 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途
HK40008907A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
BR122024018467A2 (pt) Formulações de aminoácido e usos das mesmas

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230907

R150 Certificate of patent or registration of utility model

Ref document number: 7352901

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150